Proven performance. The LifeStent™ Vascular Stent is FDA-approved stent for the SFA and full popliteal artery.
Long term sustained effectiveness up to three years, and treatment superiority over balloon angioplasty.
Engineered for bending, compression, and torsion with dynamic vessel conformability.
Available in 6 mm and 7 mm diameters; and 150 mm to 170 mm in length.
Additionally, the LifeStent™ Solo™ Vascular Stent is available in 6 mm and 7 mm diameters and 200 mm in length.
1. As of December 2020
2. Laird et al. Nitinol Stent Implantation vs. Balloon Angioplasty for Lesions in the Superficial Femoral and Proximal Popliteal Arteries of Patients With Claudication: Three-Year Follow-up From the RESILIENT Randomized Trial. J Endovasc Ther. 2012;19:1-9. The LifeStent® 5 mm diameter was not included in this trial.
3. RESILIENT I Trial, RESILIENT II Trial, E-TAGIUSS Trial, Retrospective Analysis of LifeStent® Vascular Stent Systems in the Treatment of Long-Segment Lesions, LifeStent® Vascular Stent Delivery System Study (LifeStent® 200 mm Trial),REALITY I Trial,REALITY II Trial, ETAP Trial, CONTINUUM Trial, and RELIABLE Trial. Additional trials ongoing.
Please consult Instructions for Use for product indications for use, contraindications, warnings, precautions, complications, adverse events and detailed safety information.
Not all products and services may be available in your area. Please contact a BD representative for more information.
BD's collection of literature on industry and on our offerings gives you information you can use to continue striving for excellence.
BD offers training resources to help improve your clinical practices as part of our goal of advancing the world of health.
BD supports the healthcare industry with market-leading products and services that aim to improve care while lowering costs.
BD promotes clinical excellence by providing various resources on best practices, clinical innovations and industry trends in healthcare.
1. As of December 2020
2. Laird et al. Nitinol Stent Implantation vs. Balloon Angioplasty for Lesions in the Superficial Femoral and Proximal Popliteal Arteries of Patients With Claudication: Three-Year Follow-up From the RESILIENT Randomized Trial. J Endovasc Ther. 2012;19:1-9. The LifeStent® 5 mm diameter was not included in this trial.
3. RESILIENT I Trial, RESILIENT II Trial, E-TAGIUSS Trial, Retrospective Analysis of LifeStent® Vascular Stent Systems in the Treatment of Long-Segment Lesions, LifeStent® Vascular Stent Delivery System Study (LifeStent® 200 mm Trial),REALITY I Trial,REALITY II Trial, ETAP Trial, CONTINUUM Trial, and RELIABLE Trial. Additional trials ongoing.
Please consult Instructions for Use for product indications for use, contraindications, warnings, precautions, complications, adverse events and detailed safety information.
Not all products and services may be available in your area. Please contact a BD representative for more information.
BD-23530
